Karen S. Lynch - 01 Apr 2023 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Issuer symbol
CVS
Transactions as of
01 Apr 2023
Net transactions value
+$11,241,245
Form type
4
Filing time
04 Apr 2023, 16:32:53 UTC
Previous filing
03 Feb 2023
Next filing
05 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Tax liability $6,961,138 -93,677 -45% $74.31 112,933 01 Apr 2023 Direct F1
holding CVS Common Stock (By Trust) 304,459 01 Apr 2023 Direct
holding CVS Common Stock (Restricted) 0 01 Apr 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CVS Stock Option Award $18,202,383 +244,952 $74.31 244,952 01 Apr 2023 Common Stock 244,952 $74.31 Direct F9
holding CVS Stock Appreciation Rights 192,741 01 Apr 2023 Common Stock 192,741 $45.91 Direct F2
holding CVS Stock Appreciation Rights 93,989 01 Apr 2023 Common Stock 93,989 $37.91 Direct F3
holding CVS Stock Option 242,408 01 Apr 2023 Common Stock 242,408 $54.19 Direct F4
holding CVS Stock Option 211,196 01 Apr 2023 Common Stock 211,196 $58.34 Direct F5, F6
holding CVS Stock Option 224,604 01 Apr 2023 Common Stock 224,604 $74.30 Direct F7
holding CVS Stock Option 171,517 01 Apr 2023 Common Stock 171,517 $101.09 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Surrender of shares in payment of withholding taxes due upon the vesting and settlement of a performance stock unit award.
F2 Represents unvested Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Plan on February 17, 2017 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vest in two substantially equal annual installments beginning on February 17, 2019.
F3 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F4 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F5 The number of shares subject to the option were calculated using a 30-day average price.
F6 Option became exercisable in four equal installments, commencing 4/1/2021.
F7 Option became exercisable in four equal installments, commencing 4/1/2022.
F8 Option became exercisable in four equal installments, commencing 4/1/2023.
F9 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.